PHARMACEUTICALS

Our vision is to create a meaningful impact on human lives with high-quality solutions, driven by excellence in manufacturing and sustainability.

LOXIM is confidently leveraging its decades of expertise in manufacturing dyes and engineering plastics as it expands into the pharmaceutical industry. Our commitment to innovation and precision in chemistry enables us to offer a comprehensive range of APIs, Intermediates, KSM, and CMO/CDMO capabilities to meet the needs of the global pharmaceutical market. Our top-tier R&D facility can handle complex chemical synthesis, analytical methods development, and testing. LOXIM aims to be a responsible business, adding value through its core competency in chemistry while adhering to its core values.

60,000 Sq. Mt.

Greenfield project dedicated to the manufacturing of intermediates and APIs

Kilo Lab

Designed to facilitate the seamless scaling from R&D lab quantities to kilo quantities

OUR PHARMA PROFILE

API • INTERMEDIATES • KSM • CMO • CDMO CAPABILITIES

No Therapeutic Class API Intermediate Name Abbreviation CAS No.
1 Anticoagulant Apixaban 1-(4-Aminophenyl)-5,6-dihydro-3-(4-morpholinyl)-2(1H)-pyridinone AMP 1267610-26-3
Ethyl-2-chloro-2-(2-(4-methoxyphenyl)hydrazineylidene)acetate MPHA 27143-07-3
2 Antibiotic Avibactam (2S,5R)-6-(Benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide BDOC 1192651-49-2
3 Anticoagulant Dabigatran 3-[(3-Amino-4-methylamino-benzoyl)-pyridin-2-yl-amino]-propionic acid ethyl ester ABPE 212322-56-0
4 Ophthalmic Dorzolamide (4S)-4-Acetamide-5,6-dihydro-6-methyl-2-sulfonamide-thio[2,3-B]thiopyran7,7-dioxide ADTD 147200-03-1
5 Antidiabetic Empagliflozin (S)-3-(4-(2-Chloro-5-iodobenzyl)phenoxy)tetrahydrofuran (Empagliflozin Iodo Compound) CIPT 915095-94-2
(S)-3-(4-(5-Bromo-2-chlorobenzyl)phenoxy)tetrahydrofuran (Empagliflozin Bromo compound) BCPT 915095-89-5
Linagliptin 8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (Linagliptin Bromo compound) BMDP 853029-57-9
6 Antiasthmatic Montelukast 2-[3-(S)-[3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl]-3-hydroxypropyl]phenyl-2-propanol CPHP 287930-77-2
[1-(Mercaptomethyl)cyclopropyl]acetic acid MCA 162515-68-6
7 Antibiotic Moxifloxacin (1S,6S)-2,8-Diazabicyclo[4.3.0]nonane DBN 151213-40-0
8 Antihypertensive Sartan 5-(4′-Bromomethyl-1,1′-biphenyl-2-Yl)-1-triphenylmethyl-1H-tetrazole TTBB 124750-51-2
4′-(Bromomethyl)-2-cyanobiphenyl (Bromo OTBN) BOTBN 114772-54-2

KEY REACTION CAPABILITIES

FRIEDEL-CRAFTS REACTION  |  GRIGNARD REACTION  |  ESCHWEILER CLARKE ALKYLATION  |  HYDROGENATION (CATALYTIC / PRESSURE)  |  HALOGENATION  |  CYANATION  |  VILSMEIER REACTION  |  SANDMEYER REACTION  |  CHIRAL RESOLUTION  |  SUZUKI COUPLING

ADVANTAGE LOXIM

Robust R&D Capabilities
At LOXIM, we invest in R&D to deliver world-class products, focusing on people, processes, and productivity.

Commitment to Sustainability
Sustainability is central to our business. We innovate to reduce our environmental impact, using eco-friendly alternatives like natural gas and top-tier effluent treatment.

Excellence in GMP and Workforce
As a global supplier, we adhere to cGMP standards and continuously upskill our workforce to maintain a competitive and compliant manufacturing environment.

Strategic Leadership
Our leadership is dedicated to long-term growth, aiming to be a trusted partner for all stakeholders.

FDA Standard Manufacturing
LOXIM’s GMP and FDA standard facilities ensure high efficiency and quality, with flexibility to meet diverse industry demands.

Global Reach
With a strong international presence, LOXIM leverages its global network to serve a diverse clientele

FACILITY